On December 7-10, the 18th Annual Conference of Dermatologists of Chinese Medical Doctor Association and the National Conference on Beauty and Dermatology (CDA 2023) were held in Shanghai, and Tianjin Tianyao Pharmaceuticals Co.,Ltd. displayed its dermatology medicines on the conference. Among them, Diflucortolone valerate cream was officially launched in the first batch.

CDA Annual Conference is the largest academic event for dermatologists in China. During the meeting, Tianjin Tianyao Pharmaceuticals Co.,Ltd. exhibited and propagate six major ointment products, namely Hydrocortisone Butyrate Cream (Youzhuoer), Clioquinol Cream(Keailin), Compound Cod Live Oil and Zine Oxide Ointment, Halometasone Cream, Adapalene Gel, and Diflucortolone valerate cream, which attracted nearly 1,000 clinical experts and doctors to stop for consultation and negotiation.

As a new generation of glucocorticoid drugs for topical use, Diflucortolone valerate cream has attracted the attention of key experts in many provinces. The company submitted the drug registration application for the drug in December 2020, and received the Drug Registration Certificate approved and issued by National Medical Products Administration in May this year. The product was officially launched through this CDA Annual Conference.

As a commonly used dermatologic drug, Diflucortolone valerate cream has a global market scale of hundreds of millions of dollars. According to IQVIA data, the global sales of Diflucortolone valerate cream in 2020 and 2021 were $109 million and $116 million respectively.

It is learned that the drug was first developed by Schering Germany, with commodity name of Nerisona, which was a gap in domestic market before. The official production and launching of the product this time filled this gap and highlighted the leading position of Tianjin Tianyao Pharmaceuticals Co.,Ltd. in the field of corticosteroids.